X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (18) 18
humans (17) 17
male (16) 16
female (15) 15
chronic myeloid leukemia (14) 14
aged (12) 12
aged, 80 and over (12) 12
hematology (12) 12
middle aged (11) 11
oncology (11) 11
adult (10) 10
treatment outcome (10) 10
follow-up studies (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (8) 8
young adult (7) 7
adolescent (6) 6
antineoplastic agents - therapeutic use (5) 5
chronic myelogenous leukemia (5) 5
cml (5) 5
imatinib (5) 5
management (5) 5
protein kinase inhibitors - therapeutic use (5) 5
recommendations (5) 5
breccia (4) 4
cardiac & cardiovascular systems (4) 4
child (4) 4
follow-up (4) 4
italy - epidemiology (4) 4
leukemia (4) 4
leukemia, myelogenous, chronic, bcr-abl positive - complications (4) 4
molecular response (4) 4
myeloid leukemia (4) 4
pyrimidines - adverse effects (4) 4
tyrosine (4) 4
adenocarcinoma (3) 3
age (3) 3
analysis (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
care and treatment (3) 3
chronic-phase (3) 3
clonality (3) 3
comorbidity (3) 3
gastric stump tumor (3) 3
hematology, oncology and palliative medicine (3) 3
imatinib mesylate (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - epidemiology (3) 3
leukemia, myeloid, chronic-phase - drug therapy (3) 3
medicine & public health (3) 3
molecular analysis (3) 3
nilotinib (3) 3
p53 (3) 3
population (3) 3
pyrimidines - administration & dosage (3) 3
pyrimidines - therapeutic use (3) 3
quality of life (3) 3
retrospective studies (3) 3
risk factors (3) 3
therapy (3) 3
time factors (3) 3
tyrosine kinase inhibitors (3) 3
yolk sac type (3) 3
adverse events (2) 2
age factors (2) 2
aged patients (2) 2
antineoplastic agents - adverse effects (2) 2
benzamides - therapeutic use (2) 2
cancer (2) 2
cardiac patients (2) 2
cardiopatias congênitas (2) 2
child, preschool (2) 2
children (2) 2
chronic myeloid leukaemia (2) 2
cml patients (2) 2
comorbidities (2) 2
criança (2) 2
cytogenetic response (2) 2
dasatinib (2) 2
disease-free survival (2) 2
drug therapy (2) 2
elderly (2) 2
elderly-patients (2) 2
exercícios de alongamento muscular (2) 2
frontline nilotinib (2) 2
heart defects, congenital (2) 2
hemic and lymphatic diseases (2) 2
imatinib mesylate - administration & dosage (2) 2
impact (2) 2
incidence (2) 2
infant (2) 2
life (2) 2
physics (2) 2
piperazines - therapeutic use (2) 2
prevention (2) 2
prophylaxis (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein-tyrosine kinase (2) 2
protein-tyrosine kinases - antagonists & inhibitors (2) 2
quality-of-life (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer, ISSN 0008-543X, 05/2018, Volume 124, Issue 10, pp. 2228 - 2237
Journal Article
Leukemia Research, ISSN 0145-2126, 2015, Volume 39, Issue 10, pp. 1055 - 1059
Journal Article
Leukemia Research, ISSN 0145-2126, 11/2018, Volume 74, pp. 75 - 79
Journal Article
Journal Article
Hematological Oncology, ISSN 0278-0232, 08/2019, Volume 37, Issue 3, pp. 296 - 302
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2018, Volume 97, Issue 1, pp. 95 - 100
Pleural effusion (PE) represents the leading cause of dasatinib (DAS) discontinuation. However, the pathogenic mechanism of this adverse event (AE) is unknown... 
Dasatinib | Medicine & Public Health | Hematology | Pleural effusion | Oncology | Chronic myeloid leukemia | Molecular response | Dose reduction | CHRONIC MYELOGENOUS LEUKEMIA | MANAGEMENT | CHRONIC-PHASE | 2ND-LINE DASATINIB | FOLLOW-UP | EUROPEAN-LEUKEMIANET | INTOLERANT | RECOMMENDATIONS | IMATINIB | HEMATOLOGY | ELDERLY-PATIENTS | Pleural effusions | Care and treatment
Journal Article
Drugs & Aging, ISSN 1170-229X, 8/2013, Volume 30, Issue 8, pp. 629 - 637
A large number of chronic myeloid leukemia (CML) patients are treated with imatinib mesylate outside of clinical trials, which may not be representative of... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Geriatrics/Gerontology | SURVIVAL | CML | MYELOPROLIFERATIVE DISORDERS | SAFETY | TYROSINE KINASE | PROGNOSTIC SCORE | FOLLOW-UP | PHARMACOLOGY & PHARMACY | MESYLATE THERAPY | AGE | GERIATRICS & GERONTOLOGY | Piperazines - administration & dosage | Follow-Up Studies | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Benzamides - therapeutic use | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Aging | Female | Retrospective Studies | Benzamides - adverse effects | Comorbidity | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Protein Kinase Inhibitors - administration & dosage | Leukemia, Myeloid, Chronic-Phase - epidemiology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Italy - epidemiology | Aged | Drug Monitoring | Cohort Studies | Drug therapy | Chronic myeloid leukemia | Research | Index Medicus
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 11/2018, Volume 271, pp. 54 - 59
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 08/2019, Volume 288, pp. 124 - 127
Journal Article
Haematologica, ISSN 0390-6078, 09/2016, Volume 101, Issue 10, pp. 1200 - 1207
Journal Article
Haematologica, ISSN 0390-6078, 08/2017, Volume 102, Issue 9, pp. 1530 - 1536
Journal Article